Agentanbud
✅ Öppen Ingen deadline angiven

Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel

Tidsplan

Publicerad 2024-10-14
Deadline —

Beskrivning

Tilldelat till: Bristol-Myers Squibb AB | Vinnarland: SWE | Beslutsdatum: 2024-10-07Z

Klassificering

CPV-koder
  • 33600000 Läkemedel
Procedur neg-wo-call

Om köparen

Region Skåne har 38 öppna upphandlingar på Agentanbud just nu, och 275 annonser i vår data.

Köper oftast: Medicinsk utrustning, läkemedel och hygienartiklar · Laboratorieutrustning, optisk utrustning och precisionsutrustning (exkl. glas) · Arkitekt-, bygg-, ingenjörs- och besiktningstjänster.

Flest kontrakt 2021–2024, enligt Upphandlingsmyndighetens statistik över 1953 kontrakterade anbud: Medtronic Aktiebolag (25) · B. Braun Medical Aktiebolag (22) · Accord Healthcare AB (22).

Allt om Region Skåne →

Åtgärder

✅ TED EU är helt publikt — inget konto krävs för att se dokument.

Rådata (JSON)
{
  "title-proc": {
    "swe": "Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel"
  },
  "publication-number": "619792-2024",
  "contract-conclusion-date": [
    "2024-10-08Z"
  ],
  "winner-country": [
    "SWE"
  ],
  "organisation-country-buyer": [
    "SWE"
  ],
  "duration-period-value-lot": [
    "4"
  ],
  "framework-agreement-lot": [
    "fa-wo-rc"
  ],
  "place-of-performance-country-proc": [
    "SWE"
  ],
  "winner-identifier": [
    "556092-9886"
  ],
  "procedure-type": "neg-wo-call",
  "classification-cpv": [
    "33600000",
    "33600000"
  ],
  "publication-date": "2024-10-14+02:00",
  "buyer-name": {
    "swe": [
      "Region Skåne, Koncernstab inköp och ekonomistyrning"
    ]
  },
  "winner-decision-date": [
    "2024-10-07Z"
  ],
  "contract-nature-main-proc": "supplies",
  "links": {
    "xml": {
      "MUL": "https://ted.europa.eu/en/notice/619792-2024/xml"
    },
    "pdf": {
      "BUL": "https://ted.europa.eu/bg/notice/619792-2024/pdf",
      "SPA": "https://ted.europa.eu/es/notice/619792-2024/pdf",
      "CES": "https://ted.europa.eu/cs/notice/619792-2024/pdf",
      "DAN": "https://ted.europa.eu/da/notice/619792-2024/pdf",
      "DEU": "https://ted.europa.eu/de/notice/619792-2024/pdf",
      "EST": "https://ted.europa.eu/et/notice/619792-2024/pdf",
      "ELL": "https://ted.europa.eu/el/notice/619792-2024/pdf",
      "ENG": "https://ted.europa.eu/en/notice/619792-2024/pdf",
      "FRA": "https://ted.europa.eu/fr/notice/619792-2024/pdf",
      "GLE": "https://ted.europa.eu/ga/notice/619792-2024/pdf",
      "HRV": "https://ted.europa.eu/hr/notice/619792-2024/pdf",
      "ITA": "https://ted.europa.eu/it/notice/619792-2024/pdf",
      "LAV": "https://ted.europa.eu/lv/notice/619792-2024/pdf",
      "LIT": "https://ted.europa.eu/lt/notice/619792-2024/pdf",
      "HUN": "https://ted.europa.eu/hu/notice/619792-2024/pdf",
      "MLT": "https://ted.europa.eu/mt/notice/619792-2024/pdf",
      "NLD": "https://ted.europa.eu/nl/notice/619792-2024/pdf",
      "POL": "https://ted.europa.eu/pl/notice/619792-2024/pdf",
      "POR": "https://ted.europa.eu/pt/notice/619792-2024/pdf",
      "RON": "https://ted.europa.eu/ro/notice/619792-2024/pdf",
      "SLK": "https://ted.europa.eu/sk/notice/619792-2024/pdf",
      "SLV": "https://ted.europa.eu/sl/notice/619792-2024/pdf",
      "FIN": "https://ted.europa.eu/fi/notice/619792-2024/pdf",
      "SWE": "https://ted.europa.eu/sv/notice/619792-2024/pdf"
    },
    "pdfs": {
      "SWE": "https://ted.europa.eu/sv/notice/619792-2024/pdfs"
    },
    "html": {
      "BUL": "https://ted.europa.eu/bg/notice/-/detail/619792-2024",
      "SPA": "https://ted.europa.eu/es/notice/-/detail/619792-2024",
      "CES": "https://ted.europa.eu/cs/notice/-/detail/619792-2024",
      "DAN": "https://ted.europa.eu/da/notice/-/detail/619792-2024",
      "DEU": "https://ted.europa.eu/de/notice/-/detail/619792-2024",
      "EST": "https://ted.europa.eu/et/notice/-/detail/619792-2024",
      "ELL": "https://ted.europa.eu/el/notice/-/detail/619792-2024",
      "ENG": "https://ted.europa.eu/en/notice/-/detail/619792-2024",
      "FRA": "https://ted.europa.eu/fr/notice/-/detail/619792-2024",
      "GLE": "https://ted.europa.eu/ga/notice/-/detail/619792-2024",
      "HRV": "https://ted.europa.eu/hr/notice/-/detail/619792-2024",
      "ITA": "https://ted.europa.eu/it/notice/-/detail/619792-2024",
      "LAV": "https://ted.europa.eu/lv/notice/-/detail/619792-2024",
      "LIT": "https://ted.europa.eu/lt/notice/-/detail/619792-2024",
      "HUN": "https://ted.europa.eu/hu/notice/-/detail/619792-2024",
      "MLT": "https://ted.europa.eu/mt/notice/-/detail/619792-2024",
      "NLD": "https://ted.europa.eu/nl/notice/-/detail/619792-2024",
      "POL": "https://ted.europa.eu/pl/notice/-/detail/619792-2024",
      "POR": "https://ted.europa.eu/pt/notice/-/detail/619792-2024",
      "RON": "https://ted.europa.eu/ro/notice/-/detail/619792-2024",
      "SLK": "https://ted.europa.eu/sk/notice/-/detail/619792-2024",
      "SLV": "https://ted.europa.eu/sl/notice/-/detail/619792-2024",
      "FIN": "https://ted.europa.eu/fi/notice/-/detail/619792-2024",
      "SWE": "https://ted.europa.eu/sv/notice/-/detail/619792-2024"
    },
    "htmlDirect": {
      "BUL": "https://ted.europa.eu/bg/notice/619792-2024/html",
      "SPA": "https://ted.europa.eu/es/notice/619792-2024/html",
      "CES": "https://ted.europa.eu/cs/notice/619792-2024/html",
      "DAN": "https://ted.europa.eu/da/notice/619792-2024/html",
      "DEU": "https://ted.europa.eu/de/notice/619792-2024/html",
      "EST": "https://ted.europa.eu/et/notice/619792-2024/html",
      "ELL": "https://ted.europa.eu/el/notice/619792-2024/html",
      "ENG": "https://ted.europa.eu/en/notice/619792-2024/html",
      "FRA": "https://ted.europa.eu/fr/notice/619792-2024/html",
      "GLE": "https://ted.europa.eu/ga/notice/619792-2024/html",
      "HRV": "https://ted.europa.eu/hr/notice/619792-2024/html",
      "ITA": "https://ted.europa.eu/it/notice/619792-2024/html",
      "LAV": "https://ted.europa.eu/lv/notice/619792-2024/html",
      "LIT": "https://ted.europa.eu/lt/notice/619792-2024/html",
      "HUN": "https://ted.europa.eu/hu/notice/619792-2024/html",
      "MLT": "https://ted.europa.eu/mt/notice/619792-2024/html",
      "NLD": "https://ted.europa.eu/nl/notice/619792-2024/html",
      "POL": "https://ted.europa.eu/pl/notice/619792-2024/html",
      "POR": "https://ted.europa.eu/pt/notice/619792-2024/html",
      "RON": "https://ted.europa.eu/ro/notice/619792-2024/html",
      "SLK": "https://ted.europa.eu/sk/notice/619792-2024/html",
      "SLV": "https://ted.europa.eu/sl/notice/619792-2024/html",
      "FIN": "https://ted.europa.eu/fi/notice/619792-2024/html",
      "SWE": "https://ted.europa.eu/sv/notice/619792-2024/html"
    }
  },
  "winner-name": {
    "swe": [
      "Bristol-Myers Squibb AB"
    ]
  },
  "notice-title": {
    "hun": "Svédország – Gyógyszerészeti termékek – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "lav": "Zviedrija – Farmācijas izstrādājumi – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "swe": "Sverige – Läkemedel – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "gle": "An tSualainn – Pharmaceutical products – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "ell": "Σουηδία – Φαρμακευτικά προϊόντα – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "spa": "Suecia – Productos farmacéuticos – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "est": "Rootsi – Ravimid – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "nld": "Zweden – Farmaceutische producten – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "fin": "Ruotsi – Farmaseuttiset tuotteet – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "pol": "Szwecja – Produkty farmaceutyczne – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "hrv": "Švedska – Farmaceutski proizvodi – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "ces": "Švédsko – Léčivé přípravky a zdravotnické prostředky – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "dan": "Sverige – Lægemidler – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "ron": "Suedia – Produse farmaceutice – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "por": "Suécia – Produtos farmacêuticos – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "slk": "Švédsko – Farmaceutické výrobky – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "fra": "Suède – Produits pharmaceutiques – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "mlt": "L-Iżvezja – Prodotti farmaċewtiċi – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "deu": "Schweden – Arzneimittel – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "lit": "Švedija – Farmacijos produktai – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "ita": "Svezia – Prodotti farmaceutici – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "bul": "Швeция – Фармацевтични продукти – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "slv": "Švedska – Farmacevtski proizvodi – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel",
    "eng": "Sweden – Pharmaceutical products – Läkemedlet Breyanzi - substansen lisokabtagen-maraleucel"
  },
  "buyer-city": {
    "mul": [
      "KRISTIANSTAD"
    ]
  }
}